Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
December 10, 2021 16:01 ET
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell...
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
December 08, 2021 01:13 ET
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell...
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock
December 07, 2021 16:16 ET
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell...
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
December 06, 2021 07:00 ET
|
Adicet Bio
Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma (ORR=75%, CR=50%)No ADI-001-related serious...
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin’s Lymphoma
November 29, 2021 07:00 ET
|
Adicet Bio
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON,...
Adicet Announces Appointment of Dr. Michael G. Kauffman to the Board of Directors
November 18, 2021 07:00 ET
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...
Adicet Presents Preclinical Data for ADI-002, a GPC3-Targeted Development Candidate for Solid Tumors, at the SITC Annual Meeting
November 12, 2021 07:00 ET
|
Adicet Bio
Adicet’s allogeneic gamma delta CAR-T cell therapy candidate is designed to combine CAR targeting and cell intrinsic IL-15 armoring with the innate and adaptive immune effector functions of the...
Adicet Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021 16:01 ET
|
Adicet Bio
On track to report top-line safety and tolerability data from ADI-001 Phase 1 study in Non-Hodgkin's Lymphoma (NHL) by year endAnnounced collaboration with Twist Bioscience to accelerate discovery of...
Adicet Bio to Participate in Stifel 2021 Virtual Healthcare Conference
November 08, 2021 07:00 ET
|
Adicet Bio
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for...
Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting
November 04, 2021 09:00 ET
|
Adicet Bio
MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell...